scholarly journals Introduction to “Immunotherapies for Multiple Myeloma”

2020 ◽  
Vol 13 (11) ◽  
pp. 396
Author(s):  
Massimo Offidani ◽  
Maria Teresa Petrucci
Keyword(s):  
Multiple Myeloma ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Hematological Cancer ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Multiple myeloma (MM) is the second most common hematological cancer after diffuse large B-cell lymphoma, accounting for about 10% of all blood cancers [...]

scholarly journals A bendamustine resistance gene signature in diffuse large B-cell lymphoma and multiple myeloma

2020 ◽  
Author(s):  
Issa Ismail Issa ◽  
Rasmus Froberg Brøndum ◽  
Hanne Due ◽  
Linnéa Schmidt ◽  
Martin Bøgsted ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
B Cell ◽  
Resistance Gene ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Gene Signature ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

2016 ◽  
Vol 34 (23) ◽  
pp. 2698-2704 ◽  
Author(s):  
Alexander M. Lesokhin ◽  
Stephen M. Ansell ◽  
Philippe Armand ◽  
Emma C. Scott ◽  
Ahmad Halwani ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
T Cell ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Peripheral T Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
T Cell Lymphomas ◽  
Large B Cell

Purpose Cancer cells can exploit the programmed death-1 (PD-1) immune checkpoint pathway to avoid immune surveillance by modulating T-lymphocyte activity. In part, this may occur through overexpression of PD-1 and PD-1 pathway ligands (PD-L1 and PD-L2) in the tumor microenvironment. PD-1 blockade has produced significant antitumor activity in solid tumors, and similar evidence has emerged in hematologic malignancies. Methods In this phase I, open-label, dose-escalation, cohort-expansion study, patients with relapsed or refractory B-cell lymphoma, T-cell lymphoma, and multiple myeloma received the anti–PD-1 monoclonal antibody nivolumab at doses of 1 or 3 mg/kg every 2 weeks. This study aimed to evaluate the safety and efficacy of nivolumab and to assess PD-L1/PD-L2 locus integrity and protein expression. Results Eighty-one patients were treated (follicular lymphoma, n = 10; diffuse large B-cell lymphoma, n = 11; other B-cell lymphomas, n = 10; mycosis fungoides, n = 13; peripheral T-cell lymphoma, n = 5; other T-cell lymphomas, n = 5; multiple myeloma, n = 27). Patients had received a median of three (range, one to 12) prior systemic treatments. Drug-related adverse events occurred in 51 (63%) patients, and most were grade 1 or 2. Objective response rates were 40%, 36%, 15%, and 40% among patients with follicular lymphoma, diffuse large B-cell lymphoma, mycosis fungoides, and peripheral T-cell lymphoma, respectively. Median time of follow-up observation was 66.6 weeks (range, 1.6 to 132.0+ weeks). Durations of response in individual patients ranged from 6.0 to 81.6+ weeks. Conclusion Nivolumab was well tolerated and exhibited antitumor activity in extensively pretreated patients with relapsed or refractory B- and T-cell lymphomas. Additional studies of nivolumab in these diseases are ongoing.

The course of anxiety, depression and unmet needs in survivors of diffuse large B cell lymphoma and multiple myeloma in the early survivorship period

2017 ◽  
Vol 11 (3) ◽  
pp. 329-338 ◽  
Author(s):  
Devesh Oberoi ◽  
Victoria White ◽  
John Seymour ◽  
H. Miles Prince ◽  
Simon Harrison ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
B Cell ◽  
Unmet Needs ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Anxiety Depression ◽  
Large B Cell

scholarly journals Prevalence of Cytoplasmic Actin Mutations in Diffuse Large B-Cell Lymphoma and Multiple Myeloma: A Functional Assessment Based on Actin Three-Dimensional Structures

2020 ◽  
Vol 21 (9) ◽  
pp. 3093 ◽  
Author(s):  
Laura Witjes ◽  
Marleen Van Troys ◽  
Bruno Verhasselt ◽  
Christophe Ampe
Keyword(s):  
Multiple Myeloma ◽  
B Cell ◽  
Cell Lymphoma ◽  
3D Structure ◽  
Three Dimensional ◽  
B Cell Lymphoma ◽  
Mutational Frequency ◽  
Large B Cell Lymphoma ◽  
Hematological Cancers ◽  
Large B Cell

Mutations in actins have been linked to several developmental diseases. Their occurrence across different cancers has, however, not been investigated. Using the cBioPortal database we show that human actins are infrequently mutated in patient samples of various cancers types. Nevertheless, ranking these studies by mutational frequency suggest that some have a higher percentage of patients with ACTB and ACTG1 mutations. Within studies on hematological cancers, mutations in ACTB and ACTG1 are associated with lymphoid cancers since none have currently been reported in myeloid cancers. Within the different types of lymphoid cancers ACTB mutations are most frequent in diffuse large B-cell lymphoma (DLBCL) and ACTG1 mutations in multiple myeloma. We mapped the ACTB and ACTG1 mutations found in these two cancer types on the 3D-structure of actin showing they are in regions important for actin polymer formation or binding to myosin. The potential effects of the mutations on actin properties imply that mutations in cytoplasmic actins deserve dedicated research in DLBCL and multiple myeloma.

Multiple bone lesions and hypercalcemia presented in diffuse large B cell lymphoma: mimicking multiple myeloma?

2010 ◽  
Vol 91 (4) ◽  
pp. 716-722 ◽  
Author(s):  
Ping Chen ◽  
Bingzong Li ◽  
Wenzhuo Zhuang ◽  
Haiwen Huang ◽  
Hong Zhang ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Bone Lesions ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Synthetic control arms in studies of multiple myeloma and diffuse large B‐cell lymphoma

2021 ◽  
Author(s):  
Rahul Banerjee ◽  
Shonali Midha ◽  
Amar H. Kelkar ◽  
Aaron Goodman ◽  
Vinay Prasad ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Synthetic Control ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Concomitant occurrence of multiple myeloma with diffuse large B-cell lymphoma

2016 ◽  
Vol 59 (3) ◽  
pp. 427 ◽  
Author(s):  
Subhashis Mitra ◽  
Sanghamitra Mukherjee ◽  
Jay Mehta ◽  
Maitreyee Bhattacharyya ◽  
Hema Chakraborty
Keyword(s):  
Multiple Myeloma ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell
Sign in / Sign up

Export Citation Format

Share Document